The Procam Challenge: A Hidden Opportunity
Procam (Procalcitonin) is a biomarker indicating severe bacterial infection. While crucial for timely intervention, its potential in identifying comorbidities and predicting clinical outcomes is often overlooked. This gap in patient understanding presents a significant opportunity for pharmaceutical companies.
The Cost of Missed Opportunities
Failing to identify Procam-related risks can lead to:
- Increased hospitalization rates
- Higher treatment costs
- Deteriorating patient outcomes
- Negative impact on drug efficacy
These consequences not only affect patients but also impact a pharmaceutical company’s bottom line and reputation.
Kribado: Your Solution to the Procam Challenge
Kribado is a groundbreaking risk stratification and behavior setting device designed to address the limitations of traditional patient screening methods. By instantly providing a Procam risk score, Kribado empowers healthcare professionals to:
- Identify high-risk patients early
- Optimize patient care pathways
- Enhance clinical trial recruitment
- Drive data-driven decision-making
How Kribado Works
Kribado’s user-friendly interface and advanced algorithms make patient screening efficient and accurate. With a simple touch-screen and embedded printer, healthcare providers can:
- Collect patient data effortlessly
- Generate instant Procam risk scores
- Identify potential comorbidities
- Inform treatment decisions
Indigital Technologies: Your Partner in Patient Care
- Optimize patient engagement
- Improve clinical trial outcomes
- Enhance brand reputation
- Achieve sustainable growth
As pharmaceutical business growth experts, Indigital Technologies has a proven track record of driving success for over 653 brands across 8 countries. Our expertise, combined with innovative solutions like Kribado, empowers you to:
With a strong foundation of 3 patents and a stellar service rating of 4.2 stars, we are committed to delivering exceptional value to our clients.